Vikram Pattanayak

6.0k total citations · 2 hit papers
24 papers, 4.4k citations indexed

About

Vikram Pattanayak is a scholar working on Molecular Biology, Infectious Diseases and Oncology. According to data from OpenAlex, Vikram Pattanayak has authored 24 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 3 papers in Infectious Diseases and 3 papers in Oncology. Recurrent topics in Vikram Pattanayak's work include CRISPR and Genetic Engineering (13 papers), Advanced biosensing and bioanalysis techniques (7 papers) and RNA and protein synthesis mechanisms (5 papers). Vikram Pattanayak is often cited by papers focused on CRISPR and Genetic Engineering (13 papers), Advanced biosensing and bioanalysis techniques (7 papers) and RNA and protein synthesis mechanisms (5 papers). Vikram Pattanayak collaborates with scholars based in United States, United Kingdom and Italy. Vikram Pattanayak's co-authors include David R. Liu, J. Keith Joung, Shengdar Q. Tsai, Michelle S. Prew, Benjamin P. Kleinstiver, Nathalie T. Nguyen, Zongli Zheng, John P. Guilinger, Steven Lin and Enbo Ma and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Vikram Pattanayak

21 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects

2016 2.0k citations Benjamin P. Kleinstiver, Vikram Pattanayak et al. Nature profile →
High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity

2013 1.2k citations Vikram Pattanayak, Steven Lin et al. Nature Biotechnology profile →

Peers

Countries citing papers authored by Vikram Pattanayak

Since Specialization

Citations

This map shows the geographic impact of Vikram Pattanayak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vikram Pattanayak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vikram Pattanayak more than expected).

Fields of papers citing papers by Vikram Pattanayak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vikram Pattanayak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vikram Pattanayak. The network helps show where Vikram Pattanayak may publish in the future.

Co-authorship network of co-authors of Vikram Pattanayak

This figure shows the co-authorship network connecting the top 25 collaborators of Vikram Pattanayak. A scholar is included among the top collaborators of Vikram Pattanayak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vikram Pattanayak. Vikram Pattanayak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Low-Intensity Conditioning Regimen with Fludarabine Achieved Mixed Chimerism and Minimization of Immunosuppression without Cytokine Release Syndrome 2025 ·American Journal of Transplantation ·(unknown), Ryo Otsuka, Thomas R. Spitzer, Nahel Elias, Vikram Pattanayak, (unknown), (unknown), David H. Sachs, (unknown), Leonardo V. Riella	0
2	Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations 2023 ·Drug Design Development and Therapy ·(unknown), Vikram Pattanayak, Ryan J. Sullivan	18
3	CRISPR-Cas9 treatment partially restores amyloid-β 42/40 in human fibroblasts with the Alzheimer’s disease PSEN1 M146L mutation 2022 ·Molecular Therapy — Nucleic Acids ·(unknown), (unknown), (unknown), (unknown), Sarah M. Fayad, Daniel Y. Kim, Karl Petri, Martin J. Aryee, (unknown), Bence György, Vilmantas Giedraitis, J. Keith Joung, Vikram Pattanayak, Magnus Essand, Anna Erlandsson, Oksana Berezovska, Martin Ingelsson	28
4	Suboptimal antibody response against SARS-CoV-2 Omicron variant after third dose of mRNA vaccine in kidney transplant recipients 2022 ·Kidney International ·Ayman Al Jurdi, Rodrigo Benedetti Gassen, Thiago J. Borges, Isadora T. Lape, Leela Morená, Orhan Efe, Zhabiz Solhjou, (unknown), (unknown), (unknown), Vikram Pattanayak, Camille N. Kotton, Jamil Azzi, Leonardo V. Riella	34
5	Non-Invasive Monitoring for Rejection in Kidney Transplant Recipients After SARS-CoV-2 mRNA Vaccination 2022 ·Frontiers in Immunology ·Ayman Al Jurdi, Rodrigo Benedetti Gassen, Thiago J. Borges, Zhabiz Solhjou, (unknown), Isadora T. Lape, Orhan Efe, (unknown), (unknown), John Y. Choi, (unknown), (unknown), Vikram Pattanayak, Ivy A. Rosales, Paolo Cravedi, Camille N. Kotton, Jamil Azzi, Leonardo V. Riella	20
6	Analysis of off-target effects in CRISPR-based gene drives in the human malaria mosquito 2021 ·Proceedings of the National Academy of Sciences ·William T. Garrood, Nace Kranjc, Karl Petri, Daniel Y. Kim, Jimmy A. Guo, Andrew Hammond, Ioanna Morianou, Vikram Pattanayak, J. Keith Joung, Andrea Crisanti, Alekos Simoni	23
7	A Code of Ethics for Gene Drive Research 2021 ·The CRISPR Journal ·George J. Annas, Chase L. Beisel, Kendell Clement, Andrea Crisanti, Stacy A. Francis, Marco Galardini, Roberto Galizi, Julian Grünewald, (unknown), Ahmad S. Khalil, Ruth Müller, Vikram Pattanayak, Karl Petri, Ligi Paul, Luca Pinello, Alekos Simoni, Chrysanthi Taxiarchi, J. Keith Joung	29
8	Finding platelets: Don't let the perfect be the enemy of the good 2021 ·Transfusion ·Patricia A. R. Brunker, Vikram Pattanayak, Grace K. Mahowald	0
9	Association between Human Leukocyte Antigen Type and Keratinocyte Carcinoma Risk in Renal Transplant Recipients 2019 ·Journal of Investigative Dermatology ·Yuhree Kim, (unknown), Vikram Pattanayak, Hang Lee, Maryam M. Asgari	3
10	177 Specific HLA types increase risk of keratinocyte carcinoma in renal transplant recipients 2018 ·Journal of Investigative Dermatology ·Y. Kim, Vikram Pattanayak, (unknown), (unknown), Maryam M. Asgari	1
11	High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects breakdown → 2016 ·Nature ·Benjamin P. Kleinstiver, Vikram Pattanayak, Michelle S. Prew, Shengdar Q. Tsai, Nathalie T. Nguyen, Zongli Zheng, J. Keith Joung	1967
12	Small molecule–triggered Cas9 protein with improved genome-editing specificity 2015 ·Nature Chemical Biology ·(unknown), Vikram Pattanayak, David B. Thompson, John A. Zuris, David R. Liu	340
13	Determining the Specificities of TALENs, Cas9, and Other Genome-Editing Enzymes 2014 ·Methods in enzymology on CD-ROM/Methods in enzymology ·Vikram Pattanayak, John P. Guilinger, David R. Liu	56
14	Broad specificity profiling of TALENs results in engineered nucleases with improved DNA-cleavage specificity 2014 ·Nature Methods ·John P. Guilinger, Vikram Pattanayak, Deepak Reyon, Shengdar Q. Tsai, Jeffry D. Sander, J. Keith Joung, David R. Liu	163
15	In silico abstraction of zinc finger nuclease cleavage profiles reveals an expanded landscape of off-target sites 2013 ·Nucleic Acids Research ·Jeffry D. Sander, Cherie L. Ramirez, Samantha J Linder, Vikram Pattanayak, Noam Shoresh, Manching Ku, (unknown), Deepak Reyon, B Bernstein, David R. Liu, J. Keith Joung	44
16	High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity breakdown → 2013 ·Nature Biotechnology ·Vikram Pattanayak, Steven Lin, John P. Guilinger, Enbo Ma, Jennifer A. Doudna, David R. Liu	1155
17	Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection 2011 ·Nature Methods ·Vikram Pattanayak, Cherie L. Ramirez, J. Keith Joung, David R. Liu	346
18	Observed versus predicted structure of fluorescent self-quenching reporter molecules (SQRM): Caveats with respect to the use of “stem–loop” oligonucleotides as probes for mRNA folding 2008 ·RNA ·Vikram Pattanayak, Lida K. Gifford, Ponzy Lu, Alan M. Gewirtz	2
19	Directed Evolution and Substrate Specificity Profile of Homing Endonuclease I-SceI 2006 ·Journal of the American Chemical Society ·Jeffrey B. Doyon, Vikram Pattanayak, (unknown), David R. Liu	94
20	Stemless self-quenching reporter molecules identify target sequences in mRNA 2005 ·Analytical Biochemistry ·Lida K. Gifford, (unknown), Vikram Pattanayak, (unknown), Ting Bao, Alan M. Gewirtz, Ponzy Lu	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact